The vaccination of Catalans between 70 and 79 years starts this Monday

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on pocket
Pocket
Share on whatsapp
WhatsApp
  • Spain will receive, from Tuesday until June, 5.5 million of the single-dose drugs of Janssen

  • When everyone over 70 is immunized, the mortality due to covid-19 it will drop by 75%

Catalonia will start vaccinate against covid-19 a the age group between 70 and 79, in a generalized way, from this Monday, April 12. Even so, in some parts of the territory such as Lleida or areas of the province of Barcelona, ​​this group began to be cited days ago.

The Ministry of Health will begin to inoculate the drug in descending order (that is, it will start with the 79-year-olds and so on). These people will be cited through a SMS (with a link from which day and time can be arranged) and they will be clicked on the primary care centers (CAP). For now, they will be Pfizer vaccine.

The ‘conselleria’ is finalizing the immunization of the group over 80 years: 85.3% have already received the first dose and 27.3% the second. Salut foresees get to June with everyone over 70 vaccinated. When these have been punctured, mortality from covid-19 will drop by 75%, according to estimates from the Computational Biology and Complex Systems Group (Biocomsc) of the Universitat Politècnica de Catalunya (UPC).

However, it will not be until the over 60 are vaccinated when the sick in ucis. In Catalonia, 1,306,475 people have already been vaccinated with the first dose (16.8% of the total population), of which 462,249 (one 5,9%) they have also received the second. Experts ask to reach a 30% or 35% of the vaccinated population to enjoy a certain normality, although the group immunity will be reached when the 70% of the population.

Read Also:  Workers look back: "I sometimes thought, is this life?"

Janssen vaccines

Spain will receive on Tuesday, first thing in the morning, the first Janssen vaccines, that only require one dose. The country will receive 5.5 million vials of this drug between April and June.

The Minister of Health, Carolina Darias, said this Saturday that the Janssen vaccine “will be applied in accordance with the latest update of the vaccination strategy in the same typology as RNA; in other words, it will converge from 80 years downwards. “

Likewise, it has said that the Government is analyzing various possibilities for people under the age of 60 who have received a first dose of AstraZeneca, since now this drug will only be used in people over 60. One of them would be to receive a second dose of another RNA vaccine, as has been done in Germany and France. Another alternative would be that these people are not vaccinated again with another dose, as studies ensure that the first dose of AstraZeneca achieves a 70% immunity.

Darias insisted that the decision will be made according to the scientific criteria that the experts decide and has stressed that there is time to decide.

Janssen and the EMA

Furthermore, the European Medicines Agency (EMA) is investigating the risk of developing thromboembolisms with the Janssen covid-19 vaccine, subsidiary of the American Johnson & Johnson, upon receiving a “safety signal” related to four severe cases of blood clotting after vaccination with this preparation.

As confirmed by the EMA on Friday, and after the meetings held by its security committee (PRAC) from last Tuesday to this Friday, its experts have begun a “review” of cases to investigate thromboembolic events or the formation of blood clots unusual in people vaccinated with Janssen.

Read Also:  Alert! Diabetes Can Worsen Covid-19 Infection

The EMA analyzes data on four severe cases of unusual blood clotting with low platelets in patients who had previously received this vaccine, one of them during the clinical trial and three during the use of Janssen in United States, of which, one resulted in the death of the vaccinated person.

It may interest you

“These reports point to a ‘safety sign’, but it is currently unclear if there is a causal association between vaccination with Janssen and these conditions. The PRAC is investigating these cases and will decide if a regulatory action may be necessary, which generally consists of an update of the product information ”, clarified the EMA in a summary of the meetings of the PRAC this week.

Although it received the approval of the EMA almost a month ago, Janssen’s vaccine is still not used in the European Union (EU) due to delays in the delivery of doses by the pharmacist, so, for now, only being used in the United States with an emergency use authorization to immunize against covid-19.

.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on pocket
Pocket
Share on whatsapp
WhatsApp

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.